Emmes Appoints Matt Bond as CFO
Press Release
Reportedly, Matt Bond’s expertise in mergers and acquisitions (M&A) and his track record with successful private-equity-backed enterprises are expected to be valuable assets in Emmes’ growth and diversification strategy.
US-based Clinical Research Organisation (CRO) Emmes has named Matt Bond as its Chief Financial Officer (CFO), succeeding former CFO Brian Hochheimer.
This decision aligns with Emmes’ objective of supporting the advancement of public health and biopharmaceutical innovation. By appointing a seasoned financial executive with deep industry knowledge, Emmes is positioning itself for sustained growth and an increased impact across the healthcare sector.
On his appointment, Bond said, “This is a perfect time to join the company, as we continue to build our reputation with government and biopharma clients and ramp up our presence in new global markets. I’m able to hit the ground running because I’ve worked in this sector for decades and have been successful in generating profitable growth while partnering with strong management teams.”
Prior to joining Emmes, Bond served as CFO of Bracket (now Signant Health), a leading technology provider to the drug development market. During his tenure, he oversaw sustained organizational growth, including the successful sale of the company to another global, private-equity-backed firm.
Earlier in his career, Bond co-founded Aptiv Solutions, a technology-focused CRO, where he played a key role in growing the company from a startup into a multinational organization through the acquisition of more than 10 companies.
Commenting on the appointment, Peter Ronco, CEO of Emmes, said, “Matt combines a rich set of CFO experiences with a deep understanding of the biopharma and clinical technology solutions space. A seasoned executive with more than 30 years of financial leadership experience, he has led the finance function for many successful private-equity-backed companies in the pharmaceutical services and contract research market segment.”
Earlier this month, Emmes appointed Peter Ronco as Chief Executive Officer, succeeding Dr. Christine Dingivan, who has transitioned to the role of Senior Advisor to Executive Chairman Sastry Chilukuri and Emmes’ Board of Directors.
Ronco is an experienced global pharmaceutical executive with more than two decades of leadership across multiple R&D roles. Most recently, he served as Senior Vice President of Global Development at Johnson & Johnson, where he oversaw the management and execution of a drug development portfolio comprising more than 500 active clinical studies across all therapeutic areas and development phases. He has also held senior leadership positions at Bristol Myers Squibb, Accenture, and Pfizer.
Founded in 1977, Emmes is a global, full-service Clinical Research Organisation (CRO) headquartered in the United States. The organization supports the advancement of public health and biopharmaceutical innovation and has conducted more than 2,000 clinical studies across a wide range of therapeutic areas, including infectious diseases, vaccines, ophthalmology, oncology, neurology, substance use disorders, and maternal and child health.
Emmes currently operates offices across the United States, Europe, Canada, and India. The company reported annual revenues of approximately $110 million for the 2022 fiscal year.
In a related development, Mankind Pharma appointed former VFS executive Tarun Kapoor as Vice President earlier this year, aiming to strengthen its digital strategy and position the company for future growth.
Go back to Newsroom
Reportedly, Matt Bond’s expertise in mergers and acquisitions (M&A) and his track record with successful private-equity-backed enterprises are expected to be valuable assets in Emmes’ growth and diversification strategy.
US-based Clinical Research Organisation (CRO) Emmes has named Matt Bond as its Chief Financial Officer (CFO), succeeding former CFO Brian Hochheimer.
This decision aligns with Emmes’ objective of supporting the advancement of public health and biopharmaceutical innovation. By appointing a seasoned financial executive with deep industry knowledge, Emmes is positioning itself for sustained growth and an increased impact across the healthcare sector.
On his appointment, Bond said, “This is a perfect time to join the company, as we continue to build our reputation with government and biopharma clients and ramp up our presence in new global markets. I’m able to hit the ground running because I’ve worked in this sector for decades and have been successful in generating profitable growth while partnering with strong management teams.”
Prior to joining Emmes, Bond served as CFO of Bracket (now Signant Health), a leading technology provider to the drug development market. During his tenure, he oversaw sustained organizational growth, including the successful sale of the company to another global, private-equity-backed firm.
Earlier in his career, Bond co-founded Aptiv Solutions, a technology-focused CRO, where he played a key role in growing the company from a startup into a multinational organization through the acquisition of more than 10 companies.
Commenting on the appointment, Peter Ronco, CEO of Emmes, said, “Matt combines a rich set of CFO experiences with a deep understanding of the biopharma and clinical technology solutions space. A seasoned executive with more than 30 years of financial leadership experience, he has led the finance function for many successful private-equity-backed companies in the pharmaceutical services and contract research market segment.”
Earlier this month, Emmes appointed Peter Ronco as Chief Executive Officer, succeeding Dr. Christine Dingivan, who has transitioned to the role of Senior Advisor to Executive Chairman Sastry Chilukuri and Emmes’ Board of Directors.
Ronco is an experienced global pharmaceutical executive with more than two decades of leadership across multiple R&D roles. Most recently, he served as Senior Vice President of Global Development at Johnson & Johnson, where he oversaw the management and execution of a drug development portfolio comprising more than 500 active clinical studies across all therapeutic areas and development phases. He has also held senior leadership positions at Bristol Myers Squibb, Accenture, and Pfizer.
Founded in 1977, Emmes is a global, full-service Clinical Research Organisation (CRO) headquartered in the United States. The organization supports the advancement of public health and biopharmaceutical innovation and has conducted more than 2,000 clinical studies across a wide range of therapeutic areas, including infectious diseases, vaccines, ophthalmology, oncology, neurology, substance use disorders, and maternal and child health.
Emmes currently operates offices across the United States, Europe, Canada, and India. The company reported annual revenues of approximately $110 million for the 2022 fiscal year.
In a related development, Mankind Pharma appointed former VFS executive Tarun Kapoor as Vice President earlier this year, aiming to strengthen its digital strategy and position the company for future growth.